LEP and obesity due to melanocortin 4 receptor deficiency: Under obesity conditions, the pharmacological capability of these compounds to achieve a “partial” reduction of bioactive leptin levels has shown crucial benefits, including an enhanced leptin sensitivity in the central nervous system and a higher degree of peripheral leptin sensitivity (28).